Eidos Therapeutics Inc. (EIDX)

55.13
0.51 0.92
NASDAQ : Health Technology
Prev Close 55.64
Open 55.74
Day Low/High 53.83 / 56.98
52 Wk Low/High 11.15 / 58.84
Volume 189.66K
Avg Volume 179.00K
Exchange NASDAQ
Shares Outstanding 37.50M
Market Cap 2.16B
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Eidos Therapeutics Reports Third Quarter 2019 Financial Results And Business Update

Eidos Therapeutics Reports Third Quarter 2019 Financial Results And Business Update

SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc.

EIDX Crosses Above Average Analyst Target

EIDX Crosses Above Average Analyst Target

In recent trading, shares of Eidos Therapeutics Inc have crossed above the average analyst 12-month target price of $45.00, changing hands for $47.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (NASDAQ:...

Eidos Therapeutics To Present At The 2019 Cantor Global Healthcare Conference

Eidos Therapeutics To Present At The 2019 Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc.

EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. For Potential Securities Violations And Breach Of Fiduciary Duty

EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. For Potential Securities Violations And Breach Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Eidos Therapeutics, Inc.

Eidos Therapeutics Special Committee Rejects Proposal From BridgeBio Pharma To Acquire Shares

Eidos Therapeutics Special Committee Rejects Proposal From BridgeBio Pharma To Acquire Shares

Eidos Therapeutics, Inc. (Nasdaq:EIDX) ("Eidos") announced today that the Special Committee of its Board of Directors (the "Special Committee") unanimously rejected the non-binding proposal dated August 8, 2019 (the "Proposal") from BridgeBio Pharma, Inc.

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Jim Cramer says if you want to see the U.S. economy's strength, look to Home Depot, where the consumer's confidence and influence remains healthy.

Canopy Growth, Okta, B&G Foods: 'Mad Money' Lightning Round

Canopy Growth, Okta, B&G Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Canopy Growth, Okta, B&G Foods, Eidos Therapeutics, Select Medical Holdings and more.

Eidos Therapeutics Confirms Receipt Of Non-Binding Proposal From BridgeBio Pharma To Acquire Shares

Eidos Therapeutics Confirms Receipt Of Non-Binding Proposal From BridgeBio Pharma To Acquire Shares

Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the "Company") today confirmed that it has received a non-binding proposal dated August 8, 2019 (the "Proposal") from BridgeBio Pharma, Inc.

Eidos Therapeutics Reports Second Quarter 2019 Financial Results

Eidos Therapeutics Reports Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc.

EIDX Crosses Above Average Analyst Target

EIDX Crosses Above Average Analyst Target

In recent trading, shares of Eidos Therapeutics Inc have crossed above the average analyst 12-month target price of $38.28, changing hands for $39.17/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Eidos Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Eidos Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Eidos Therapeutics, Inc. - EIDX

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Eidos Therapeutics, Inc. - EIDX

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Eidos Therapeutics, Inc.

Eidos Therapeutics Is Now Oversold (EIDX)

Eidos Therapeutics Is Now Oversold (EIDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Why Red-Hot IPO Market Will Soon Bring Financial Carnage

Why Red-Hot IPO Market Will Soon Bring Financial Carnage

The day of reckoning could be lurking for the market because of trends in the red-hot IPO market. Be prepared.

3 'Pound the Table' Calls for Stock Market Caution

3 'Pound the Table' Calls for Stock Market Caution

Misplaced confidence, IPO mania and historically high valuations mean it's increasingly important for investors to recognize potential negatives on the investment horizon.